Losec

DRUG4 trials

Sponsors

Norgine, Ajou University School of Medicine, Cinclus Pharma Holding AB

Conditions

Acid RefluxGastro Oesophageal Reflux DiseaseGastroesophageal RefluxHealthy VolunteersStomach Ulcer

Early Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study

CompletedNCT03105375

Cinclus Pharma Holding ABHealthy Volunteers

Start: 2017-02-21End: 2017-10-12Updated: 2026-06-17

Phase 1

A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions

CompletedNCT01710995

NorgineAcid Reflux, Gastro Oesophageal Reflux Disease

Start: 2010-10-31End: 2011-02-28Updated: 2012-10-19

Pharmacodynamics and Safety of CDFR0209

CompletedNCT02710994

Ajou University School of MedicineGastroesophageal Reflux, Stomach Ulcer

Start: 2014-05-31End: 2015-03-31Updated: 2016-03-17

Phase 3

Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

CompletedNCT01493089

NorgineGastroesophageal Reflux

Start: 2011-04-30End: 2011-10-31Updated: 2013-08-13

Related Papers

Challenges of Correlating pH Change with Relief of Clinical Symptoms in Gastro Esophageal Reflux Disease: A Phase III, Randomized Study of Zegerid versus Losec

PLoS ONE2015-02-2313 citations